- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01444391
inVENT-visIOn Study (inVENT-visIOn)
September 20, 2014 updated by: Acclarent
A Clinical Study of the Acclarent Tympanostomy Tube Delivery and Iontophoresis Systems In-Office
The objective of the study is to evaluate the safety and efficacy of the Acclarent Tympanostomy Tube Delivery System (TDS) for the placement of Tympanostomy Tube TT(s) under local anesthesia delivered by iontophoresis in an office/clinic setting.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
42
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Port St. Lucie, Florida, United States, 34952
- South Coast Ear, Nose, & Throat
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 months and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Scheduled to undergo tympanostomy tube insertion
- At least 6 months old
- Behavioral capacity and cooperative temperament to undergo an awake procedure (based on physician judgement)
- No history of sensitivity or reaction to anesthesia chosen for the procedure
Exclusion Criteria:
- Pregnant or lactating females
- Significantly atrophic, bimeric, or completely atelectatic tympanic membrane
- Otitis externa
- Lacerations or abrasions to the external auditory canal or damaged or denuded skin in the auditory canal
- Cerumen impaction resulting in a significant amount of cleaning required to visualize the tympanic membrane
- Electrically sensitive subjects and subjects with electrically sensitive support systems (pacemakers, defibrillators, etc.)
- Anatomy that precludes sufficient visualization of and access to the tympanic membrane
- Anatomy that necessitates tympanostomy tube placement in the posterior half of the tympanic membrane
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tympanostomy Tube Placement
|
Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system following delivery of anesthetic with Acclarent iontophoresis device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects With Procedural, Serious and Device-related Adverse Events.
Time Frame: Procedure through 2 weeks post-procedure
|
Adverse events which are procedural, serious, and device-related.
|
Procedure through 2 weeks post-procedure
|
Device Success
Time Frame: Day 0 (day of procedure)
|
Device Success is defined as the successful delivery of the tympanostomy tube (TT) across the tympanic membrane (TM) using the Tube Delivery System(TDS).
Device Success will be evaluated on a per device basis.
|
Day 0 (day of procedure)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Procedure Success
Time Frame: Day 0 (day of procedure)
|
Procedure Success is defined as the successful placement of any tympanostomy tube in all enrolled ears in a given subject.
Procedure Success is determined on a per subject basis.
|
Day 0 (day of procedure)
|
Procedure Tolerability
Time Frame: Day 0 (day of procedure)
|
Procedure Tolerability is defined as the proportion of subjects reporting the procedure as tolerable, where tolerable is defined as a score of 0 through 3, using the Wong-Baker FACES pain scale.The Wong-Baker FACES pain scoring system is a scale of 0 to 5, where 0 means 'no hurt', 1 = 'hurts a little bit', 2 = 'hurts little more', 3 = 'hurts even more', 4 = 'hurts whole lot' and 5 = 'hurts worst'.
Procedure Tolerability will be determined on a per patient basis, with the patient's score being the average of the scores for the left and right ear if both ears are successfully treated with the Tube Delivery System.
|
Day 0 (day of procedure)
|
Tube Retention
Time Frame: 2 weeks post-procedure
|
Tube retention is the presence of a tympanostomy tube placed successfully by the Tula TDS device across the tympanic membrane at the two-week follow-up visit.
|
2 weeks post-procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jacob W. Zeiders, M.D., South Coast Ear, Nose & Throat
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2011
Primary Completion (Actual)
May 1, 2012
Study Completion (Actual)
June 1, 2012
Study Registration Dates
First Submitted
September 23, 2011
First Submitted That Met QC Criteria
September 29, 2011
First Posted (Estimate)
September 30, 2011
Study Record Updates
Last Update Posted (Estimate)
October 1, 2014
Last Update Submitted That Met QC Criteria
September 20, 2014
Last Verified
September 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CPR005022
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Otitis Media
-
David Chi, MDRecruitingRecurrent Acute Otitis Media | Chronic Otitis Media With Effusion | Otitis Media in ChildrenUnited States
-
Bezmialem Vakif UniversityCompleted
-
Alcon ResearchCompletedOtitis Media With Effusion in Children | Otitis Media Recurrent
-
Medical College of WisconsinNational Institutes of Health (NIH); National Institute on Deafness and Other... and other collaboratorsRecruitingOtitis Media | Otitis Media With Effusion | Otitis Media AcuteUnited States
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceCompletedChronic Serous Otitis Media, Simple or UnspecifiedFrance
-
Tusker MedicalCompletedAOM - Acute Otitis Media | OME - Otitis Media With EffusionUnited States, Canada
-
University Hospital, GhentWithdrawn
-
Yuinvent Innovations Ltd.UnknownOtitis Media With Effusion
-
AcclarentCompletedOtitis Media With EffusionUnited States
-
Nazan DegirmenciCompleted
Clinical Trials on Tympanostomy tube placement (Acclarent iontophoresis device)
-
AcclarentCompletedOtitis Media With EffusionUnited States
-
AcclarentCompleted
-
Tusker MedicalCompletedAOM - Acute Otitis Media | OME - Otitis Media With EffusionUnited States, Canada
-
Eye & ENT Hospital of Fudan UniversityChildren's Hospital of Fudan University; Xinhua Hospital, Shanghai Jiao Tong...Not yet recruitingOtitis Media With Effusion in Children
-
Preceptis Medical, Inc.Completed
-
Smith & Nephew, Inc.RecruitingOtitis Media | Otitis Media With Effusion | Acute Otitis MediaUnited States
-
University of MinnesotaRecruitingPremature BirthUnited States
-
AventaMed DACActive, not recruiting